BIOCARDIA INC BCDA 深 滬
等待開盤 09-03 09:30:00 美东时间
1.975
-0.002
-0.10%
華盛通- 最 高1.99
- 今 開1.93
- 成交量 2.46万股
- 最 低 1.9254
- 昨 收 1.977
- 總市值 1022.64万
- 52周最高 3.2584
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.625
- 委 比 1.00%
- 總股本 517.79万
- 歷史最高 129.00
- 量 比 0.68
- 振 幅 3.27%
- 歷史最低 1.65
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology
BioCardia and CART-Tech announce an exclusive partnership to develop and commercialize Heart3D™ Fusion Imaging, enhancing 2D X-ray imaging with 3D heart models for cardiac biotherapeutic delivery and biopsy. The system integrates gold-standard MRI and CT images to improve procedural precision. BioCardia gains global exclusive rights for biotherapeutic delivery, while CART-Tech focuses on cardiac resynchronization therapy. The collaboration aims t...
08-13 12:00
BioCardia GAAP EPS of -$0.40
BioCardia press release (NASDAQ:BCDA): Q2 GAAP EPS of -$0.40. Net cash used in operations for the three months ended June 2025 was approximately $1.6 million, as compared to approximately $1.3 million...
08-12 01:58
BioCardia Q2 EPS $(0.40) Beats $(0.50) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.50) by 20 percent. This is a 54.55 percent increase over losses of $(0.88) per share from the same
08-11 21:17
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
BioCardia, Inc., a developer of cellular therapies for cardiovascular and pulmonary diseases, reported second-quarter 2025 financial results, including increased R&D expenses, lower SG&A costs, and a net loss of $2.0 million. The company highlighted progress with its CardiAMP autologous cell therapy, including successful Phase 3 trial results and ongoing submissions to Japan's PMDA and the FDA. They are also advancing the CardiAMP HF II trial and...
08-11 13:15
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
BioCardia Inc. will host a conference call on August 11, 2025, at 4:30 PM ET to discuss its Q2 2025 financial results and provide a corporate update. Participants can register via the provided link or dial-in numbers. The call will also be webcast live and available for replay afterward. BioCardia specializes in cellular therapies for cardiovascular and pulmonary diseases.
08-06 19:18
Biocardia Provides Expected Timing For Regulatory Activities For FDA And Japan PMDA Approvals Of Its CardiAMP Cell Therapy System And Helix Transendocardial Delivery Catheter
Q3 2025 Helix application for approval to FDAThe Company intends to submit for approval of the Helix Transendocardial Delivery System (Helix) to FDA as a DeNovo 510(k) application based on its safety and performance in
08-04 18:02
BioCardia Submits CardiAMP Autologous Cell Therapy Investigational Heart Failure Treatment For Clinical Consultation With Japan's Pharmaceuticals And Medical Devices Agency
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that it submitted its CardiAMP autologous cell
07-24 21:08
BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure
<p><p align="left">BioCardia, Inc. announced the submission of its investigational heart failure treatment, the CardiAMP autologous cell therapy, for clinical consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This submission includes detailed clinical data, completing the regulatory pathway for potential approval in Japan. The PMDA will review the efficacy, safety, and appropriate use of CardiAMP in heart failure patien...
07-24 13:00
港股芯片股拉升，华虹半导体涨超5%
7月24日消息，港股芯片股拉升，ASMPT涨超8%，华虹半导体涨超5%，中芯国际、上海复旦涨超3%。 7月17日，台积电公布2025年第二季度财务...
07-24 10:21
